SAN DIEGO, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Bionano Genomics, the leader in physical genome mapping, today announced that multiple presentations describing the application of its next-generation mapping (NGM) to clinically relevant human genome research will be presented at the upcoming Advances in Genome Biology and Technology (AGBT) General Meeting, February 13 – 16 in Hollywood Beach, Florida. In conjunction with the meeting, Bionano will reveal significant advances in its systems for genome analysis.
Erik Holmlin, Ph.D., CEO of Bionano, commented, “Bionano is becoming a go-to solution for researchers aiming to understand the role of genome structure and structural variations (SVs) in the biology of the human genome and genetic disorders. Studies using Bionano in critical research areas, including cancer, undiagnosed genetic disorders and muscular dystrophy, reveal insights that will prove invaluable to translational and clinical researchers seeking deeper understanding of disease and better diagnosis and treatment options for patients. Our goal is to enable researchers to discover more from genome analysis and we look forward to joining these researchers at AGBT as we reveal our next chapter.”
Bionano Key Oral Presentation:
- Oral Presentation: Use of Next-Generation Mapping in Undiagnosed Genetic Disorders
| Presenting Author: | Eric Vilain, M.D., Ph.D., Co-Director of the UCLA Clinical Genomics Center | ||||
| Evening Session: | Genome Technology | ||||
| Date, Time: | Tuesday, February 14th at 9:10 – 9:30 p.m. EST | ||||
| Location: | Great Hall 4-6 |
Bionano Key Poster Sessions:
- Poster #1009: Structural variation landscape across 26 human populations reveals population specific variation patterns in complex genomic regions
| Presenting Author: | Han Cao, Ph.D., Founder and Chief Scientific Officer at Bionano Genomics | ||||
| Date/Time: | Tuesday, February 14th at 1:00 – 2:30 p.m. EST | ||||
| Location: | Great Hall 3 |
- Poster #814: Detecting a novel range of large somatic genomic rearrangements in human cancer using the Bionano Optical mapper
| Presenting Author: | Vanessa Hayes, Ph.D., Lab Head of Human Comparative and Prostate Cancer Genomics, Garvan Institute of Medical Research | ||||
| Date/Time: | Wednesday, February 15th at 4:45 – 6:10 p.m. EST | ||||
| Location: | Great Hall 3 |
- Poster #516: Potential for improved molecular diagnosis of FSHD through D4Z4 array quantitation using Bionano technology
| Presenting Author: | Jonathan Pevsner, Ph.D., Research Scientist, Kennedy Krieger Institute and primary faculty appointment at Johns Hopkins University School of Medicine | ||||
| Date/Time: | Wednesday, February 15th at 4:45 – 6:10 p.m. EST | ||||
| Location: | Great Hall 3 |
- Poster #1116: Efficient De Novo Structural Variation Analysis and Annotation Using Next-Generation Mapping (NGM) with the BioNano Irys System
| Presenting Author: | Andy Wing Chun Pang, Ph.D., Senior Scientist at Bionano Genomics | ||||
| Date/Time: | Wednesday, February 15th at 4:45 – 6:10 p.m. EST | ||||
| Location: | Great Hall 3 |
Meet the Experts
Key researchers of the above-listed presentations will be available to discuss their experience with NGM, individual research and how NGM technology has significantly contributed to their work in prostate cancer, undiagnosed genetic disorders and muscular dystrophy. Bionano will be available onsite to discuss NGM and its next phase of development.
| Event: | Meet the Experts |
| Dates/Times: | Tuesday, February 14th at 12:00 – 1:00 p.m. EST |
| Wednesday, February 15th at 1:00 – 2:00 p.m. EST | |
| Thursday, February 16th at 10:40 – 11:05 a.m. EST | |
| Location: | Saphyr Room (# 213, 2nd Floor) |
Bionano Cocktail Hour – Roundtable discussion with our Experts
Join Bionano and key opinion leaders already utilizing NGM to expand and deepen their human genome research for an informal roundtable discussion to learn more about how NGM is enabling improved accuracy in research and analysis of the human genome and how NGM can improve your own research.
| Event: | Bionano Cocktail Hour | ||||
| Date/Time: | Tuesday, February 14th at 5:15 – 7:15 p.m. EST | ||||
| Roundtable Discussion: 6:00 p.m. EST | |||||
| Location: | Saphyr Room (# 213, 2nd Floor) |
More information about Bionano Genomics activities at AGBT 2017 is available at www.bionanogenomics.com/AGBT2017.
About Bionano Genomics
Bionano Genomics, Inc. provides next-generation mapping (NGM), which is the leading solution in physical genome mapping, offering customers whole genome analysis tools that reveal true genome structure and enabling researchers to capture what’s missing in their data to advance human, plant and animal genomic research. NGM uses NanoChannel arrays to image DNA at the single-molecule level with average single-molecule lengths of about 350,000 base pairs, which leads the genomics industry. The long-range genomic information obtained with NGM detects and deciphers structural variations (SVs), which are large, complex DNA segments involving repeats that are often missed by sequencing technologies and which are a leading cause of inaccurate and incomplete genome assembly.
As a stand-alone tool, NGM enables the accurate detection of SVs, many of which have been shown to be associated with human disease as well as complex traits in plants and animals. As a complementary tool to next-generation sequencing (NGS), NGM integrates with sequence assemblies to create contiguous hybrid scaffolds for reference-quality genome assemblies that reveal the highly informative native structure of the chromosome. NGM also provides the additional ability to verify, correct and improve a NGS-generated genome assembly.
Only Bionano provides long-range genomic information with the cost-efficiency and high throughput to keep up with advances in NGS.
NGM has been adopted by a growing number of leading institutions around the world, including: National Cancer Institute (NCI), National Institutes of Health (NIH), Wellcome Trust Sanger Institute, BGI, Garvan Institute, Salk Institute, Mount Sinai and Washington University. Investors in the Company include Domain Associates, Legend Capital, Novartis Venture Fund and Monashee Investment Management.
For more information, please visit www.BionanoGenomics.com.
Notes: Bionano Genomics is a trademark of Bionano Genomics, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.